Á¾¾çÇÐ Á¤¹ÐÀÇ·á °øµ¿ ¿¬±¸ ¹× ¶óÀ̼±½Ì °è¾à(2016-2025³â)
Precision Medicine in Oncology Collaboration and Licensing Deals 2016-2025
»óǰÄÚµå : 1727704
¸®¼­Ä¡»ç : Current Partnering, a brand of Biopharma Research Ltd.
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 450+ Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,995 £Ü 5,501,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,995 £Ü 8,256,000
PDF (Multi User License - 2 to 5 Users) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 2-5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,995 £Ü 11,010,000
PDF (Company Wide License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Á¾¾çÇÐ Á¤¹ÐÀÇ·á °øµ¿ ¿¬±¸ ¹× ¶óÀ̼±½Ì °è¾àÀº ¼¼°è ÁÖ¿ä ¹ÙÀÌ¿À±â¾÷µéÀÌ Ã¼°áÇÑ Á¾¾çÇÐ Á¤¹ÐÀÇ·á °ü·Ã °è¾à¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ÀÌÇØ¿Í Àü·Ê ¾ø´Â Á¢±Ù¼ºÀ» Á¦°øÇÕ´Ï´Ù.

º» º¸°í¼­´Â 2016³âºÎÅÍ 2025³â±îÁöÀÇ Á¾¾çÇÐ Á¤¹ÐÀÇ·á °Å·¡¿¡ ´ëÇÑ »ó¼¼ÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. ±â¾÷ÀÌ Á¾¾çÇÐ Á¤¹ÐÀÇ·á °Å·¡¿¡ Âü¿©ÇÏ´Â ¹æ¹ý°ú ÀÌÀ¯¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀÌÇØ¿Í ºÐ¼®À» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °Å·¡´Â °øµ¿ ¿¬±¸°³¹ß¿¡¼­ ½ÃÀÛÇÏ¿© ¼º°ú¹°ÀÇ »ó¾÷È­±îÁö ¿©·¯ ¿ä¼Ò¸¦ Æ÷ÇÔÇÏ´Â °æÇâÀÌ ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡´Â °øµ¿ ¿¬±¸, °³¹ß, ¿¬±¸, ¶óÀ̼±½Ì °Å·¡°¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡´Â 2016³â ÀÌÈÄ ¹ßÇ¥µÈ 879°ÇÀÇ Á¾¾çÇÐ Á¤¹ÐÀÇ·á °Å·¡¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ¸ñ·ÏÀÌ Æ÷ÇԵǾî ÀÖÀ¸¸ç, °Å·¡ ´ç»çÀÚ°¡ °ø°³ÇÑ ½ÇÁ¦ Á¾¾çÇÐ Á¤¹ÐÀÇ·á Á¦ÈÞ °Å·¡ÀÇ ¿Â¶óÀÎ °Å·¡ ±â·Ï¿¡ ´ëÇÑ ¸µÅ©µµ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ¿ë °¡´ÉÇÑ °æ¿ì ±â¾÷°ú ÆÄÆ®³Ê°¡ Áõ±Ç°Å·¡À§¿øÈ¸¿¡ Á¦ÃâÇÑ °è¾à ¹®¼­µµ ±â·ÏµÇ¾î ÀÖ½À´Ï´Ù.

º» º¸°í¼­ÀÇ Ã¹ ¹øÂ° Àå¿¡¼­´Â Á¾¾çÇп¡¼­ÀÇ Á¤¹ÐÀÇ·á °Å·¡¿¡ ´ëÇØ ¼³¸íÇÕ´Ï´Ù.

1Àå¿¡¼­´Â º» º¸°í¼­ÀÇ ¼Ò°³¿¡ ´ëÇØ ¼³¸íÇÕ´Ï´Ù.

2Àå¿¡¼­´Â 2016³â ÀÌÈÄ ¾Ï ¿µ¿ªÀÇ Á¤¹ÐÀÇ·á °Å·¡ µ¿ÇâÀ» °³°ýÀûÀ¸·Î »ìÆìº¾´Ï´Ù.

3Àå¿¡¼­´Â 2016³â ÀÌÈÄ ´ëÇ¥ÀûÀÎ Á¾¾çÇÐ Á¤¹ÐÀÇ·á °Å·¡¿¡ ´ëÇØ »ìÆìº¾´Ï´Ù. °Å·¡´Â °Å·¡±Ý¾× ±âÁØÀ¸·Î ³ª¿­µÇ¾î ÀÖ½À´Ï´Ù.

4Àå¿¡¼­´Â Á¾¾çÇÐ Á¤¹ÐÀÇ·á °Å·¡¿¡ °¡Àå Àû±ØÀûÀÎ »óÀ§ 25°³ ±â¾÷ÀÇ Á¾ÇÕÀûÀÎ ¸ñ·Ï°ú °£·«ÇÑ ¿ä¾àÀ» Á¦°øÇϰí, À̾ Á¾¾çÇÐ Á¤¹ÐÀÇ·á °Å·¡ÀÇ Á¾ÇÕÀûÀÎ ¸ñ·Ï°ú °ø°³µÈ °è¾à ¹®¼­¸¦ Á¦°øÇÕ´Ï´Ù.

5Àå¿¡¼­´Â 2016³â 1¿ù ÀÌÈÄ Ã¼°á ¹× ¹ßÇ¥µÇ¾î °è¾à ¹®¼­°¡ °ø°³µÈ Á¾¾çÇÐ Á¤¹ÐÀÇ·á ºÐ¾ß °è¾à¿¡ ´ëÇÑ Æ÷°ýÀûÀÌ°í »ó¼¼ÇÑ °ËÅ並 ÁøÇàÇÕ´Ï´Ù.

6Àå¿¡¼­´Â 2016³â 1¿ù ÀÌÈÄ Ã¼°á ¹× ¹ßÇ¥µÈ Á¾¾çÇÐ Á¤¹ÐÀÇ·á Á¦ÈÞ¸¦ Æ÷°ýÀûÀÌ°í »ó¼¼ÇÏ°Ô °ËÅäÇϰí ÀÖ½À´Ï´Ù. º» ÀåÀº ÁýÁßÇϰí Àִ ƯÁ¤ ¾Ï ¿µ¿ªÀÇ Á¤¹ÐÀÇ·á ±â¼ú À¯Çüº°·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù.

¶ÇÇÑ, 2016³â ÀÌÈÄ Á¾¾çÇÐ Á¤¹ÐÀÇ·á ºÐ¾ßÀÇ Á¤¹ÐÀÇ·á °úÁ¦ µ¿Çâ°ú Ȱµ¿À» º¸¿©ÁÖ´Â ´Ù¼öÀÇ µµÇ¥°¡ ¼ö·ÏµÇ¾î ÀÖ½À´Ï´Ù.

¶ÇÇÑ, Á¾ÇÕÀûÀÎ °Å·¡ µð·ºÅ丮´Â ±â¾÷ A-Z, °Å·¡ À¯Çü, Ä¡·á ´ë»óº°·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. °¢ °Å·¡ Á¦¸ñÀº À¥ ¸µÅ©¸¦ ÅëÇØ ¿Â¶óÀÎ ¹öÀüÀÇ °Å·¡ ±â·Ï¿¡ ¿¬°áµÇ¸ç, °¡´ÉÇÑ °æ¿ì °è¾à ¹®¼­µµ °Ô½ÃµÇ¾î ÀÖ¾î Çʿ信 µû¶ó °¢ °è¾à ¹®¼­¿¡ ½±°Ô Á¢±ÙÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ÀåÁ¡

Á¾¾çÇÐ Á¤¹ÐÀÇ·á °øµ¿ ¿¬±¸ ¹× ¶óÀ̼±½º °è¾àÀº µ¶Àڵ鿡°Ô ´ÙÀ½°ú °°Àº ÁÖ¿ä ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù:

Á¶»ç ¹üÀ§

Á¾¾çÇÐ Á¤¹ÐÀÇ·á ºÐ¾ßÀÇ °øµ¿ ¿¬±¸ ¹× ¶óÀ̼±½º °è¾àÀº ´ÙÀ½°ú °°½À´Ï´Ù:

°è¾à¼­ ºÐ¼®À» ÅëÇØ ´ÙÀ½°ú °°Àº ½Ç»ç°¡ °¡´ÉÇÕ´Ï´Ù:

¸ñÂ÷

ÁÖ¿ä ¿ä¾à

Á¦1Àå ¼Ò°³

Á¦2Àå Á¾¾çÇÐ Á¤¹ÐÀÇ·á °Å·¡ µ¿Çâ

Á¦3Àå ÁÖ¿ä Á¾¾çÇÐ Á¤¹ÐÀÇ·á °Å·¡

Á¦4Àå °¡Àå Ȱ¹ßÇÑ Á¾¾çÇÐ Á¤¹ÐÀÇ·á °Å·¡¾÷ü

Á¦5Àå Á¾¾çÇÐ Á¤¹ÐÀÇ·á °Å·¡ µð·ºÅ丮

Á¦6Àå Á¾¾çÇÐ Á¤¹ÐÀÇ·á °Å·¡ - ±â¼ú À¯Çüº°

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Precision Medicine in Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the precision medicine in oncology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of precision medicine in oncology deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter precision medicine in oncology deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 879 precision medicine in oncology deals announced since 2016 including financial terms where available including links to online deal records of actual precision medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of precision medicine in oncology dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in precision medicine in oncology dealmaking since 2016.

Chapter 3 provides an overview of the leading precision medicine in oncology deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in precision medicine in oncology dealmaking with a brief summary followed by a comprehensive listing of precision medicine in oncology deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of precision medicine in oncology deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of precision medicine in oncology partnering deals signed and announced since Jan 2016. The chapter is organized by specific precision medicine in oncology technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in precision medicine in oncology deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Precision Medicine in Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:

Report scope

Precision Medicine in Oncology Collaboration and Licensing Deals includes:

Analyzing contract agreements allows due diligence of:

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in precision medicine in oncology dealmaking

Chapter 3 - Leading precision medicine in oncology deals

Chapter 4 - Most active precision medicine in oncology dealmakers

Chapter 5 - Precision medicine in oncology contracts dealmaking directory

Chapter 6 - Precision medicine in oncology dealmaking by technology type

Table of figures

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â